22 June 2021
4basebio UK
Societas
("4basebio", the "Company" or the
“Group”)
Patent
application
Application filed
for protected linearised synthetic DNA
4basebio UK Societas (AIM: 4BB), the specialist life
sciences Group focused on exploiting intellectual property in the
field of gene therapies and vaccines, announces it has filed a
patent application for a novel protected and stabilised linear
synthetic DNA type, “osDNA™”*.
DNA is susceptible to degradation by nucleases which are
naturally occurring enzymes within organisms and which have a vital
role in the regulation of many cellular processes, while also
protecting against foreign DNA species. Enzymatic DNA degradation
can render gene therapies ineffective and is a substantial
consideration when developing gene therapies or DNA vaccines. The
Company’s novel osDNA™ product has demonstrated increased longevity
compared to conventional DNA types.
Unlike hpDNA™** which is a closed DNA construct, osDNA™ is open
linear DNA and incorporates all of the established benefits of
hpDNA™ over widely used plasmid DNA, in particular the absence of
bacterial backbone, antibiotic resistance genes or endotoxins.
osDNA™ therefore also benefits from a high level of purity.
Furthermore, a long terminal mono-nucleotide sequence
(homopolymeric sequence) is an essential feature of high-quality
mRNA. These types of sequences are known to be difficult to
manufacture through plasmid fermentation. osDNA™ is readily able to
incorporate these sequences, positioning osDNA™ as a highly suited
template for the production of mRNA products, an area of
significant commercial opportunity for the Company’s products and
technologies.
Dr Heikki Lanckriet, CEO and
CSO for 4basebio commented: “We are delighted to have filed
this patent, further developing and broadening our technology
portfolio. We see real opportunity to position osDNA™ as a key
input for mRNA and DNA vaccine production, an area of the rapidly
growing gene therapy and vaccine market attracting significant
attention.”
*osDNA™ = open stabilised DNA, a brand name for the
Company’s open linear DNA
** hpDNA™ = Hairpin DNA, a brand name for the
Company’s enzymatically produced DNA
For further enquiries, please
contact:
4basebio UK
Societas |
+44 (0)12 2396
7943 |
Heikki Lanckriet,
CEO |
|
|
|
Cairn Financial
Advisers LLP (Nominated Adviser) |
+44 (0)20 7213
0880 |
Jo Turner / Sandy
Jamieson |
|
|
|
finnCap Ltd
(Broker) |
+44 (0)20 7220
0500 |
Geoff Nash/Richard
Chambers/Charlotte Sutcliffe |
|
|
|
Walbrook PR |
+44 (0)20 7933
8780 |
Anna Dunphy / Paul McManus |
Mob: +44
(0)7876 441 001 / +44 (0)7980 541 893 |
|
|
|
Notes to Editors
4basebio (AIM: 4BB) is a specialist life sciences Group focused
on therapeutic DNA for gene therapies and DNA vaccines and
providing solutions for effective and safe delivery of these DNA
based products to patients. It is the intention of the Company to
become a market leader in the manufacture and supply of high
purity, synthetic DNA for research, therapeutic and pharmacological
use. The immediate objectives of 4bb are to validate and scale its
DNA synthesis and advance its collaborations to facilitate the
functional validation of its DNA based products and gene delivery
solutions.
The Company divested from 4basebio AG (“4bb AG”), a German
company listed on the Prime Standard segment of the Frankfurt Stock
Exchange, following the disposal by 4bb AG (then named Expedeon AG)
of its proteomics and immunology business to AIM-quoted Abcam plc
in January 2020 for €120million.
Following the disposal, 4bb AG retained its genomics business which
owned and licensed certain intellectual property including its
proprietary, patent-protected technology, TruePrime™. This is the
foundation for building the Company’s synthetic DNA manufacturing
business which 4bb AG transferred to the Company along with funding
to continue the Company’s development and investment.